Ovarian cancer: updated phase III data provide reassurance for the use of PARPi as maintenance therapy
Sustained benefit of PARPi treatment may help to put the recent concerns on how and when to use these agents in women into context
Is overall survival the right endpoint for PARPi trials in ovarian cancer?
Unfavourable overall survival data for PARP inhibitors in certain ovarian cancers prompts calls for caution in interpretation of the analyses and stimulates the search for surrogate measures of clinical benefit
Despite success of targeted therapies, personalised medicine is not yet a reality in ovarian cancer
Expert says widely applicable predictive testing is needed to improve prevention, diagnosis and treatment